Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-061442
Filing Date
2025-05-01
Accepted
2025-05-01 07:10:20
Documents
82
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q fulc-20250331.htm   iXBRL 10-Q 2174477
2 EX-31.1 fulc-ex31_1.htm EX-31.1 14104
3 EX-31.2 fulc-ex31_2.htm EX-31.2 14095
4 EX-32.1 fulc-ex32_1.htm EX-32.1 7909
5 EX-32.2 fulc-ex32_2.htm EX-32.2 7312
  Complete submission text file 0000950170-25-061442.txt   8995273

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT fulc-20250331.xsd EX-101.SCH 1315312
84 EXTRACTED XBRL INSTANCE DOCUMENT fulc-20250331_htm.xml XML 1540006
Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 617-651-8851
Fulcrum Therapeutics, Inc. (Filer) CIK: 0001680581 (see all company filings)

EIN.: 474839948 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38978 | Film No.: 25899375
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)